Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy
Abraham S. Kanate(HonorHealth), Mehdi Hamadani(Medical College of Wisconsin), Paul A. Carpenter(Fred Hutch Cancer Center), Navneet S. Majhail(Sarah Cannon), Richard E. Champlin(The University of Texas MD Anderson Cancer Center), Paul J. Orchard(University of Minnesota), Jeanne Palmer(Mayo Clinic), Wael Saber(Medical College of Wisconsin), Paul Veys(Great Ormond Street Hospital), Sergio Giralt(Memorial Sloan Kettering Cancer Center), Charles F. LeMaistre(CHRISTUS Transplant Institute), Bipin N. Savani(Vanderbilt University Medical Center), David I. Marks(University Hospitals Bristol NHS Foundation Trust), Christopher Bredeson, Stephen W. Crawford, James Omel(Island Institute)
Cited by 278
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
|British Journal of Haematology|1998|1.5k
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k